Andrew Moin serves as Executive at SAB Biotherapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Andrew Moin has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Sep 29, 2025 involved exercising options for 1,740,000 shares valued at $3.0M.
Andrew Moin currently holds 2,198,457 shares of SAB Biotherapeutics, Inc. (SABS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Andrew Moin has been a net neutral trader of SABS stock. They have purchased $0 and sold $0 worth of shares.
Andrew Moin's most recent insider trade was on Sep 29, 2025, when they sold 1,740,000 shares at $1.75 per share.
Get notified when new Form 4 filings are submitted
| 4,584,571 |
| $N/A |
| Discretionary |